PDCD1 and neoplasm: The fields of tumor immunology, chronic infection (e.g., HIV-1 and hepatitis C virus), vaccinology, and autoimmunity are investigating the promising prospect of checkpoint blockade immunotherapy, largely based on encouraging results in treating certain cancers with anti-PD-1/PD-L1 antibodies.